Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Amortizatization of Intangibles: 2011-2025

Historic Amortizatization of Intangibles for Arrowhead Pharmaceuticals (ARWR) over the last 15 years, with Sep 2025 value amounting to $5.8 million.

  • Arrowhead Pharmaceuticals' Amortizatization of Intangibles fell 88.82% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.8 million, marking a year-over-year increase of 78.45%. This contributed to the annual value of $5.8 million for FY2025, which is 78.45% up from last year.
  • As of FY2025, Arrowhead Pharmaceuticals' Amortizatization of Intangibles stood at $5.8 million, which was up 78.45% from $3.2 million recorded in FY2024.
  • Arrowhead Pharmaceuticals' 5-year Amortizatization of Intangibles high stood at $5.8 million for FY2025, and its period low was -$2.9 million during FY2022.
  • Its 3-year average for Amortizatization of Intangibles is $3.7 million, with a median of $3.2 million in 2024.
  • Per our database at Business Quant, Arrowhead Pharmaceuticals' Amortizatization of Intangibles plummeted by 993.98% in 2022 and then surged by 169.31% in 2023.
  • Arrowhead Pharmaceuticals' Amortizatization of Intangibles (Yearly) stood at -$266,000 in 2021, then crashed by 993.98% to -$2.9 million in 2022, then soared by 169.31% to $2.0 million in 2023, then soared by 60.83% to $3.2 million in 2024, then surged by 78.45% to $5.8 million in 2025.